Obermatt

Ono Pharmaceutical

TYO:4528 · JP3197600004
PharmaceuticalsLarge

360

87
EV / EBIT80
Price / Owner Earnings87
Owner Earnings Yield98
Dividend Yield91
Price/Sales30
EV / Gross Profit97
Price/Book75
Return on Capital29
Cash Return on Capital58
Return on Equity29
EBIT Margin45
Gross Profitability39
Cash Conversion76
Accruals78
Owner Earnings Margin78
Sales growth1
Profit Growth62
Long-Term EPS Growth17
Owner Earnings Growth76
Reinvestment1
Price momentum92
Debt load75
Refinancing25
Debt Payback100
Liquidity82
Analyst ratings5
Opinion Changes69
Price Target Upside18
Market mood65
Value Creation16/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Ono Pharmaceutical generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryJapan
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeTSE
Founded1947
Employees270
ISINJP3197600004
Last UpdateApr 2, 2026
Index & Theme
CardiovascularRheumatologyImmunologyNeurologyOsteoporosisDiabetesOncologyCentral Nervous SystemHealth CareMedicalPharmaceutical

Description

Ono Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development of neuroscience, intracellular signaling, and genomic-based drugs. The company intends to acquire commercialization rights to new drug candidates in early…

Analysis

Bargain bin

Ono Pharmaceutical Co., Ltd. falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.

The price is attractive. You pay 9.6× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -4% yearly growth; analysts expect 47%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is sturdy. The company scores 16/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
81
2023202420252026

All-time high

81

Jun 2026

All-time low

55

Jan 2024

Average rank

69

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
30
69
41
39
Price/Earnings
60
88
100
89
Price/Book
75
88
62
61
Dividend Yield
91
91
89
77
Value (overall)
78
94
84
65

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ono Pharmaceutical with its peers
Yuhan
KSC:000100
32
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Sumitomo Dainippon Pharma
TYO:4506
79
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Kyongbo Pharmaceutical
KSC:214390
11
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Tsumura
TYO:4540
47
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Pyridam Farma
JKT:PYFA
3
CountrySingapore
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sawai Pharmaceutical
TYO:4887
44
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →